Association between skin and aortic vascular inflammation in patients with psoriasis: A case-cohort study using positron emission tomography/computed tomography
- Amit K. Dey,
- Aditya A. Joshi,
- Abhishek Chaturvedi,
- Joseph B. Lerman,
- Tsion M. Aberra,
- Justin A. Rodante
- National Institutes of Health,
- University of Arizona,
- Chevy Chase Dermatology Associates,
- George Washington University,
- DermAssociates,
- National Institutes of Health, Bethesda
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>IMPORTANCE: Inflammation is critical in the development of atherosclerosis. Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by <sup>18</sup>fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events. It provides a human model to understand the effect of treating inflammation in a target organ (eg, the skin) on vascular diseases. OBJECTIVE: To investigate the association between change in skin disease severity and change in vascular inflammation at 1 year and to characterize the impact of 1 year of anti–tumor necrosis factor therapy on vascular inflammation. DESIGN, SETTING, AND PARTICIPANTS: In this prospective cohort study, 220 participants from outpatient practices were recruited at the US National Institutes of Health. A total of 115 consecutively recruited patients with psoriasis were followed up at 1 year. The study was conducted from January 1, 2013, through October 31, 2016, with data analyzed in November 2016. EXPOSURE: Skin inflammation measured as Psoriasis Area and Severity Index (PASI) score. MAIN OUTCOMES AND MEASURES: Vascular inflammation assessed as target-to-background ratio by <sup>18</sup>fluorodeoxyglucose positron emission tomography/computed tomography. RESULTS: Among the 115 patients, the mean (SD) age at 1-year follow-up was 50.8 (12.8) years and 68 were men (59%). The cohort had a low cardiovascular risk by Framingham risk score and mild-to-moderate psoriasis, with a median PASI score of 5.2 (interquartile range, 3.0-8.9). At follow-up, the total cohort had a median improvement in PASI score of 33%, with use of topical therapy (60%), biological therapy (66%, mostly anti–tumor necrosis factor) and phototherapy (15%) (P < .001). Moreover, improvement in PASI score was associated with improvement in target-to-background ratio of 6%, mainly driven by those with higher responses in PASI score (P < .001). This association persisted beyond traditional risk factors (β = 0.19; 95% CI, 0.012-0.375; P = .03) and was the strongest in those initiated with anti–tumor necrosis factor therapy (β = 0.79; 95% CI, 0.269-1.311; P = .03). CONCLUSIONS AND RELEVANCE: Improvement in psoriasis skin disease severity was associated with improvement in aortic vascular inflammation by <sup>18</sup>fluorodeoxyglucose positron emission tomography/computed tomography, with greater improvement in aortic vascular inflammation observed in those who had higher than 75% reduction in skin disease severity. These findings suggest that controlling remote target organ inflammation (eg, in the skin) may improve vascular diseases; however, randomized clinical trials are needed to confirm these findings.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 1013-1018 (6 pages)Journal (Volume, Issue Number)
JAMA Cardiology (Volume 2, Issue 9)Publication milestones
- Published - 09/2017
Publication status
Published - 09/2017
ISSN
2380-6583Publication IDs
- Scopus: 85030528453
- PubMed: 28564678
Publication metrics
Metrics
Fractional count
1
Fractional count
0.04
Fractional count
25
Fractional count
0.96
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Mentions
1
Captures
106
Citation count
109
Funding Details
Funding/Support: This study was supported by grant HL006193-01 from the National Institutes of Health Intramural Research Program. Dr Gelfand was supported by grant K24-AR-064310 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
FundersFunding numbers
NHLBI
ZIAHL006193
NIAMS
-NHRI
K24-AR-064310
